Juan M Gonzales-Morena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juan M Gonzales-Morena has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Pavel Jakoube
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
4 shared publications - Zuzana Keckesova
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
4 shared publications - Susana Machado
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
3 shared publications Yuxiong Feng
Zhejiang Provincial Key Laboratory of Pancreatic Disease, First Affiliated Hospital, and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China
3 shared publicationsAndrea Hartmanova
The Czech Center for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic
2 shared publicationsBeata Malcekova
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences
2 shared publications
Latest Publications
- Open Access
- 26 September 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (21) , 6342-6365
The role of autoproteolysis and mitoribosomal proteins in the regulation of the mitochondrial LACTB tumor suppressor
Tumor suppressors represent one of the first lines of defense against malignant transformation, and their inactivation in cells leads to the onset of tumorigenesis. Cancer cells employ various mechanisms to inactivate cellular tumor suppressors, including epigenetic silencing and mutagenesis. Less understood are the mechanisms by which cancer cells inactivate tumor suppressors post-translationally. Here, we uncovered a previously undescribed post-translational mechanism by which cancer cells inactivate the potent mitochondrial tumor suppressor LACTB in breast cancers. We discovered that the substrate of LACTB can be LACTB itself; LACTB possesses autoproteolytic activity, which is important for modulating its tumor suppressor activity. We demonstrate that cancer cells exploit this feature of LACTB to induce LACTB’s self-degradation. This is mechanistically realized through upregulation of mitochondrial MRPS34 protein, which, through interaction with LACTB, is a positive regulator of LACTB’s autoproteolytic activity and a negative regulator of LACTB. This study provides insights into how cancer cells fine-tune the expression and activity of tumor suppressors to promote tumorigenesis.
- 26 September 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (21) , 6342-6365
Open AccessThe role of autoproteolysis and mitoribosomal proteins in the regulation of the mitochondrial LACTB tumor suppressor
Tumor suppressors represent one of the first lines of defense against malignant transformation, and their inactivation in cells leads to the onset of tumorigenesis. Cancer cells employ various mechanisms to inactivate cellular tumor suppressors, including epigenetic silencing and mutagenesis. Less understood are the mechanisms by which cancer cells inactivate tumor suppressors post-translationally. Here, we uncovered a previously undescribed post-translational mechanism by which cancer cells inactivate the potent mitochondrial tumor suppressor LACTB in breast cancers. We discovered that the substrate of LACTB can be LACTB itself; LACTB possesses autoproteolytic activity, which is important for modulating its tumor suppressor activity. We demonstrate that cancer cells exploit this feature of LACTB to induce LACTB’s self-degradation. This is mechanistically realized through upregulation of mitochondrial MRPS34 protein, which, through interaction with LACTB, is a positive regulator of LACTB’s autoproteolytic activity and a negative regulator of LACTB. This study provides insights into how cancer cells fine-tune the expression and activity of tumor suppressors to promote tumorigenesis.
- Open Access
- 6 December 2023
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 7 (2) , e202302497
Correction: LACTB exerts tumor suppressor properties in epithelial ovarian cancer through regulation of Slug
We show the ability of LACTB to function as a tumor suppressor in ovarian cancer through down-regulation of Slug and induction of differentiation.
- 6 December 2023
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 7 (2) , e202302497
Open AccessCorrection: LACTB exerts tumor suppressor properties in epithelial ovarian cancer through regulation of Slug
We show the ability of LACTB to function as a tumor suppressor in ovarian cancer through down-regulation of Slug and induction of differentiation.
- Open Access
- 14 November 2022
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 6 (1) , e202201510
LACTB exerts tumor suppressor properties in epithelial ovarian cancer through regulation of Slug
Epithelial–mesenchymal transition (EMT) is a cellular mechanism used by cancer cells to acquire migratory and stemness properties. In this study, we show, through in vitro, in vivo, and 3D culture experiments, that the mitochondrial protein LACTB manifests tumor suppressor properties in ovarian cancer. We show that LACTB is significantly down-regulated in epithelial ovarian cancer cells and clinical tissues. Re-expression of LACTB negatively effects the growth of cancer cells but not of non-tumorigenic cells. Mechanistically, we show that LACTB leads to differentiation of ovarian cancer cells and loss of their stemness properties, which is achieved through the inhibition of the EMT program and the LACTB-dependent down-regulation of Snail2/Slug transcription factor. This study uncovers a novel role of LACTB in ovarian cancer and proposes new ways of counteracting the oncogenic EMT program in this model system.
- 14 November 2022
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 6 (1) , e202201510
Open AccessLACTB exerts tumor suppressor properties in epithelial ovarian cancer through regulation of Slug
Epithelial–mesenchymal transition (EMT) is a cellular mechanism used by cancer cells to acquire migratory and stemness properties. In this study, we show, through in vitro, in vivo, and 3D culture experiments, that the mitochondrial protein LACTB manifests tumor suppressor properties in ovarian cancer. We show that LACTB is significantly down-regulated in epithelial ovarian cancer cells and clinical tissues. Re-expression of LACTB negatively effects the growth of cancer cells but not of non-tumorigenic cells. Mechanistically, we show that LACTB leads to differentiation of ovarian cancer cells and loss of their stemness properties, which is achieved through the inhibition of the EMT program and the LACTB-dependent down-regulation of Snail2/Slug transcription factor. This study uncovers a novel role of LACTB in ovarian cancer and proposes new ways of counteracting the oncogenic EMT program in this model system.
- Open Access
- 28 June 2021
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (18) , 4652-4667
Mitochondrial Tumor Suppressors—The Energetic Enemies of Tumor Progression
Tumor suppressors represent a critical line of defense against tumorigenesis. Their mechanisms of action and the pathways they are involved in provide important insights into cancer progression, vulnerabilities, and treatment options. Although nuclear and cytosolic tumor suppressors have been extensively investigated, relatively little is known about tumor suppressors localized within the mitochondria. However, recent research has begun to uncover the roles of these important proteins in suppressing tumorigenesis. Here, we review this newly developing field and summarize available information on mitochondrial tumor suppressors.
- 28 June 2021
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (18) , 4652-4667
Open AccessMitochondrial Tumor Suppressors—The Energetic Enemies of Tumor Progression
Tumor suppressors represent a critical line of defense against tumorigenesis. Their mechanisms of action and the pathways they are involved in provide important insights into cancer progression, vulnerabilities, and treatment options. Although nuclear and cytosolic tumor suppressors have been extensively investigated, relatively little is known about tumor suppressors localized within the mitochondria. However, recent research has begun to uncover the roles of these important proteins in suppressing tumorigenesis. Here, we review this newly developing field and summarize available information on mitochondrial tumor suppressors.
- 17 January 2017
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 22 (45) , 6748-6758
Adduct Formation and Context Factors in Drug Hypersensitivity: Insight from Proteomic Studies
21 p.-4 fig.-1 tab.Drug hypersensitivity reactions result from the activation of the immune system by drugs or their metabolites. The clinical presentations of drug hypersensitivity can range from relatively mild local manifestations to severe systemic syndromes that can be life-threatening. As in other allergic reactions, the causes are multifactorial as genetic, metabolic and concomitant factors may influence the occurrence of drug hypersensitivity. Formation of drug protein adducts is considered a key step in drug adverse reactions, and in particular in the immunological recognition in drug hypersensitivity reactions. Nevertheless, non-covalent interactions of drugs with receptors in immune cells or with MHC clefts and/or exposed peptides can also play an important role. In recent years, development of proteomic approaches has allowed the identification and characterization of the protein targets for modification by drugs in vivo and in vitro, the nature of peptides exposed on MHC molecules, the changes in protein levels induced by drug treatment, and the concomitant modifications induced by danger signals, thus providing insight into context factors. Nevertheless, given the complexity and multifactorial nature of drug hypersensitivity reactions, understanding the underlying mechanisms also requires the integration of knowledge from genomic, metabolomic and clinical studies.This work has been supported by grants SAF2012-36519 and SAF2015-68590R from MINECO/FEDER and RETIC RD12/0013/0008 from ISCIII to D.P.-S., and by RETIC RD12/0013/0001 and CP15/00103 from ISCIII, and PI-0699-2011 and PI-0179-2014 from Junta de Andalucía to M.I.M.Peer reviewe
- 17 January 2017
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 22 (45) , 6748-6758
Adduct Formation and Context Factors in Drug Hypersensitivity: Insight from Proteomic Studies
21 p.-4 fig.-1 tab.Drug hypersensitivity reactions result from the activation of the immune system by drugs or their metabolites. The clinical presentations of drug hypersensitivity can range from relatively mild local manifestations to severe systemic syndromes that can be life-threatening. As in other allergic reactions, the causes are multifactorial as genetic, metabolic and concomitant factors may influence the occurrence of drug hypersensitivity. Formation of drug protein adducts is considered a key step in drug adverse reactions, and in particular in the immunological recognition in drug hypersensitivity reactions. Nevertheless, non-covalent interactions of drugs with receptors in immune cells or with MHC clefts and/or exposed peptides can also play an important role. In recent years, development of proteomic approaches has allowed the identification and characterization of the protein targets for modification by drugs in vivo and in vitro, the nature of peptides exposed on MHC molecules, the changes in protein levels induced by drug treatment, and the concomitant modifications induced by danger signals, thus providing insight into context factors. Nevertheless, given the complexity and multifactorial nature of drug hypersensitivity reactions, understanding the underlying mechanisms also requires the integration of knowledge from genomic, metabolomic and clinical studies.This work has been supported by grants SAF2012-36519 and SAF2015-68590R from MINECO/FEDER and RETIC RD12/0013/0008 from ISCIII to D.P.-S., and by RETIC RD12/0013/0001 and CP15/00103 from ISCIII, and PI-0699-2011 and PI-0179-2014 from Junta de Andalucía to M.I.M.Peer reviewe
Amoxicillin haptenates intracellular proteins that can be transported in exosomes to target cells
Background Allergic reactions to β‐lactams are among the most frequent causes of drug allergy and constitute an important clinical problem. Drug covalent binding to endogenous proteins (haptenation) is thought to be required for activation of the immune system. Nevertheless, neither the nature nor the role of the drug protein targets involved in this process is fully understood. Here, we aim to identify novel intracellular targets for haptenation by amoxicillin (AX) and their cellular fate. Methods We have treated B lymphocytes with either AX or a biotinylated analog (AX‐B). The identification of protein targets for haptenation by AX has been approached by mass spectrometry and immunoaffinity techniques. In addition, intercellular communication mediated by the delivery of vesicles loaded with AX‐B‐protein adducts has been explored by microscopy techniques. Results We have observed a complex pattern of AX‐haptenated proteins. Several novel targets for haptenation by AX in B lymphocytes have been identified. AX‐haptenated proteins were detected in cell lysates and extracellularly, either as soluble proteins or in lymphocyte‐derived extracellular vesicles. Interestingly, exosomes from AX‐B‐treated cells showed a positive biotin signal in electron microscopy. Moreover, they were internalized by endothelial cells, thus supporting their involvement in intercellular transfer of haptenated proteins. Conclusions These results represent the first identification of AX‐mediated haptenation of intracellular proteins. Moreover, they show that exosomes can constitute a novel vehicle for haptenated proteins, and raise the hypothesis that they could provide antigens for activation of the immune system during the allergic response.
Amoxicillin haptenates intracellular proteins that can be transported in exosomes to target cells
Background Allergic reactions to β‐lactams are among the most frequent causes of drug allergy and constitute an important clinical problem. Drug covalent binding to endogenous proteins (haptenation) is thought to be required for activation of the immune system. Nevertheless, neither the nature nor the role of the drug protein targets involved in this process is fully understood. Here, we aim to identify novel intracellular targets for haptenation by amoxicillin (AX) and their cellular fate. Methods We have treated B lymphocytes with either AX or a biotinylated analog (AX‐B). The identification of protein targets for haptenation by AX has been approached by mass spectrometry and immunoaffinity techniques. In addition, intercellular communication mediated by the delivery of vesicles loaded with AX‐B‐protein adducts has been explored by microscopy techniques. Results We have observed a complex pattern of AX‐haptenated proteins. Several novel targets for haptenation by AX in B lymphocytes have been identified. AX‐haptenated proteins were detected in cell lysates and extracellularly, either as soluble proteins or in lymphocyte‐derived extracellular vesicles. Interestingly, exosomes from AX‐B‐treated cells showed a positive biotin signal in electron microscopy. Moreover, they were internalized by endothelial cells, thus supporting their involvement in intercellular transfer of haptenated proteins. Conclusions These results represent the first identification of AX‐mediated haptenation of intracellular proteins. Moreover, they show that exosomes can constitute a novel vehicle for haptenated proteins, and raise the hypothesis that they could provide antigens for activation of the immune system during the allergic response.